Vedolizumab in IBD/PSC: A Case for Careful Vigilance?

被引：2

作者：

Jones, F. ^{[1
,2
]}

Doherty, G. A. ^{[1
,2
]}

机构：

[1] St Vincents Univ Hosp, Ctr Colorectal Dis, Elm Pk, Dublin 4, Ireland

[2] Univ Coll Dublin, Sch Med, Dublin, Ireland

来源：

JOURNAL OF CROHNS & COLITIS | 2019年 / 13卷 / 10期

关键词：

PRIMARY SCLEROSING CHOLANGITIS; DISEASE;

D O I：

10.1093/ecco-jcc/jjz102

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1237 / 1238

页数：2

共 10 条

[1] Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].

Broome, U ;

Olsson, R ;

Loof, L ;

Bodemar, G ;

Hultcrantz, R ;

Danielsson, A ;

Prytz, H ;

SandbergGertzen, H ;

Wallerstedt, S ;

Lindberg, G .

GUT, 1996, 38 (04) :610-615

[2] Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease [J].

Bye, W. A. ;

Jairath, V. ;

Travis, S. P. L. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (01) :3-15

[3] Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease [J].

Christensen, B. ;

Micic, D. ;

Gibson, P. R. ;

Yarur, A. ;

Bellaguarda, E. ;

Corsello, P. ;

Gaetano, J. N. ;

Kinnucan, J. ;

Rao, V. L. ;

Reddy, S. ;

Singh, S. ;

Pekow, J. ;

Rubin, D. T. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (06) :753-762

[4] The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium [J].

Dulai, Parambir S. ;

Singh, Siddharth ;

Jiang, Xiaoqian ;

Peerani, Farhad ;

Narula, Neeraj ;

Chaudrey, Khadija ;

Whitehead, Diana ;

Hudesman, David ;

Lukin, Dana ;

Swaminath, Arun ;

Shmidt, Eugenia ;

Wang, Shuang ;

Boland, Brigid S. ;

Chang, John T. ;

Kane, Sunanda ;

Siegel, Corey A. ;

Loftus, Edward V. ;

Sandborn, William J. ;

Sands, Bruce E. ;

Colombel, Jean-Frederic .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (08) :1147-1155

[5] Pathogenesis of Primary Sclerosing Cholangitis and Advances in Diagnosis and Management [J].

Eaton, John E. ;

Talwalkar, Jayant A. ;

Lazaridis, Konstantinos N. ;

Gores, Gregory J. ;

Lindor, Keith D. .

GASTROENTEROLOGY, 2013, 145 (03) :521-536

[6] Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis [J].

Engel, Tal ;

Ungar, Bella ;

Yung, Diana E. ;

Ben-Horin, Shomron ;

Eliakim, Rami ;

Kopylov, Uri .

JOURNAL OF CROHNS & COLITIS, 2018, 12 (02) :245-257

[7] Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis [J].

Noman, Maja ;

Ferrante, Marc ;

Bisschops, Raf ;

De Hertogh, Gert ;

Van den Broeck, Karolien ;

Rans, Karen ;

Rutgeerts, Paul ;

Vermeire, Severine ;

Van Assche, Gert .

JOURNAL OF CROHNS & COLITIS, 2017, 11 (09) :1085-1089

[8] Primary Sclerosing Cholangitis and Disease Distribution in Inflammatory Bowel Disease [J].

O'Toole, Aoibhlinn ;

Alakkari, Alaa ;

Keegan, Denise ;

Doherty, Glen ;

Mulcahy, Hugh ;

O'Donoghue, Diarmuid .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (04) :439-441

[9] Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies [J].

Tabibian, James H. ;

O'Hara, Steven P. ;

Lindor, Keith D. .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2014, 49 (08) :901-908

[10] Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease [J].

Tse, C. S. ;

Loftus, E. V., Jr. ;

Raffals, L. E. ;

Gossard, A. A. ;

Lightner, A. L. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (02) :190-195

← 1 →